Abstract Body

Background: MicroRNAs (miRs) are non-coding RNAs that regulate gene expression and can serve as biomarkers given their stability in blood and characteristic expression in various diseases. The role of extracellular miRs as potential biomarkers in HIV infection and HIV-associated cardiovascular disease (CVD) has not been described.

Methods: We analyzed the expression of 192 plasma-derived miRs from 69 HIV-infected individuals and 24 uninfected controls using Taqman miR Expression Assays and a high throughput RT-PCR instrument (Fluidigm). We also examined the association between 68 circulating miRs and flow-mediated dilatation of the brachial artery (FMD), a physiologic measure of endothelial function and a strong predictor of future CVD events, using Firefly Bioworks hydrogel particles-based miR assays. Comparisons were made using Student’s t-test, Wilcoxon rank-sum test, ANOVA, and Kruskal-Wallis test where appropriate, and false discovery rate was applied.

Results: HIV–infected individuals and controls were matched in age, gender, and traditional risk factors. The median age was 46 years (IQR 40 to 54) and 91% were men. Among the HIV patients, 72.5% were on antiretroviral therapy and 64% had an undetectable viral load. Twenty-nine miRs were differentially expressed in the plasma of HIV-infected individuals compared to controls (p<0.05 and FDR <0.15). In particular, miRs-29c, 146b, 223, and 382 have reported intracellular roles in HIV latency, and miRs-126, 145, and let-7 have been shown to be differentially expressed in coronary artery disease (CAD) among individuals without HIV. Levels of miRs-34a, 27b, and 1183 varied with different FMD quartiles (p<0.05). Thirty-eight miRs were differentially expressed in the serum of HIV-infected individuals from the low FMD quartile compared with the top FMD quartile (p<0.05; thirty miRs had FDR<0.05 and eight miRs had FDR< 0.07). In this profile, in particular, miRs-1, 133a, 133b, 208a, 208b, 499, 145, and 155 have been shown to be differentially expressed in CAD patients without HIV.

Conclusions: We demonstrate a unique miR expression profile of 29 miRs in HIV-infected individuals, as well as a unique profile of 38 miRs in HIV-infected individuals with high CVD risk and impaired endothelial function. These miR profiles may be useful in identifying HIV-infected individuals who are at increased risk for CVD, may help elucidate the underlying mechanism of HIV-associated CAD, and may be therapeutic targets for new anti-HIV drugs and CVD drugs.